Clinical Trials Logo

TP53 Gene Mutation clinical trials

View clinical trials related to TP53 Gene Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02432963 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Start date: June 14, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that have failed prior therapy, and that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving vaccine therapy together with pembrolizumab may be a better treatment in patients with solid tumors.